Skip to main content
SpringerLink
Log in
Book cover

Hepatitis B Virus in Human Diseases pp 249–276Cite as

Natural History of HBV Infection in the Community

  • Chapter

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

Abstract

The natural history of a disease is the course a disease takes in individual people, from its pathological onset, until its eventual resolution through complete recovery or death [1]. As the pathological onset of a disease is not easy to define, the natural history of a disease may also be considered to start at the moment of exposure to causal agents [1, 2]. Knowledge of the natural history of disease is important for disease prevention and control. The natural history of a disease is composed of multiple steps that ultimately lead to the occurrence of end-stage disease and or death. In the multistage pathogenesis of a disease, there exists various driving (pushing or pulling) factors that work at different stages to promote either disease progression or regression.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Porta M, editor. Natural history of disease. A dictionary of epidemiology. 5th ed. Oxford: Oxford University Press; 2014. p. 193–4.

    Google Scholar 

  2. Bhopal R. Interrelated concepts in the epidemiology of disease: natural history, spectrum, iceberg, population patterns, and screening. Concepts of epidemiology: integrating the ideas, theories, principles, and methods of epidemiology. 2nd ed. Oxford: Oxford University Press; 2008.

    Book  Google Scholar 

  3. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002;36(5):1046–9.

    Article  PubMed  Google Scholar 

  4. Chen CJ. Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements. J Hepatol. 2005;42(4):438–40.

    Article  PubMed  Google Scholar 

  5. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2(8256):1129–33.

    Article  CAS  PubMed  Google Scholar 

  6. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26(4):628–38.

    Article  PubMed  Google Scholar 

  7. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–29.

    Article  CAS  PubMed  Google Scholar 

  8. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582–92.

    Article  CAS  PubMed  Google Scholar 

  9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  10. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2(7):395–403.

    Article  PubMed  Google Scholar 

  11. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  12. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.

    Article  PubMed  Google Scholar 

  14. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.

    Article  CAS  PubMed  Google Scholar 

  15. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771–4.

    Article  CAS  PubMed  Google Scholar 

  16. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–9.

    Article  CAS  PubMed  Google Scholar 

  17. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126–35.

    Article  PubMed  Google Scholar 

  18. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974–6.

    Article  CAS  PubMed  Google Scholar 

  19. Chung DC, Ko YC, Chen CJ, Wu CC, Chen ER, Liaw YF, et al. Seroepidemiological studies on hepatitis B and D viruses infection among five ethnic groups in southern Taiwan. J Med Virol. 1988;26(4):411–8.

    Article  CAS  PubMed  Google Scholar 

  20. Chang MH, Sung JL, Lee CY, Chen CJ, Chen JS, Hsu HY, et al. Factors affecting clearance of hepatitis-B E-antigen in hepatitis-B surface-antigen carrier children. J Pediatr. 1989;115(3):385–90.

    Article  CAS  PubMed  Google Scholar 

  21. Chu CM, Liaw YF, Sheen IS, Chen TJ. Correlation of age with the status of hepatitis-B virus-replication and histological-changes in chronic type-B hepatitis. Liver. 1985;5(3):117–22.

    Article  CAS  PubMed  Google Scholar 

  22. Chu CM, Karayiannis P, Fowler MJF, Monjardino J, Liaw YF, Thomas HC. Natural-history of chronic hepatitis-B virus-infection in Taiwan – studies of hepatitis-B virus-DNA in serum. Hepatology. 1985;5(3):431–4.

    Article  CAS  PubMed  Google Scholar 

  23. Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, et al. Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10(5):527–34 e1–2.

    Article  PubMed  Google Scholar 

  24. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63(10):1648–57.

    Article  CAS  PubMed  Google Scholar 

  25. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139(2):474–82.

    Article  PubMed  Google Scholar 

  26. Liu J, Yang HI, Lee MH, Batrla R, Jen CL, Lu SN, et al. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology. 2014;60(1):77–86.

    Article  CAS  PubMed  Google Scholar 

  27. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422–7.

    Article  CAS  PubMed  Google Scholar 

  28. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–5.

    Article  CAS  PubMed  Google Scholar 

  29. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int. 2008;2:S28–36.

    Article  Google Scholar 

  30. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis-B E-antigen seroconversion in childhood – with special emphasis on the clearance of hepatitis-B E-antigen before 3 years of age. Hepatology. 1995;22(5):1387–92.

    CAS  PubMed  Google Scholar 

  31. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002;186(3):295–301.

    Article  PubMed  Google Scholar 

  32. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37(6):1309–19.

    Article  PubMed  Google Scholar 

  33. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

    Article  Google Scholar 

  34. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104–10.

    Article  PubMed  Google Scholar 

  35. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531–7.

    Article  PubMed  Google Scholar 

  36. Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58(5):853–60.

    Article  CAS  PubMed  Google Scholar 

  37. Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, et al. Predicting HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients: external validation of a scoring system. J Infect Dis. 2014;211(10):1566–73.

    Article  PubMed  Google Scholar 

  38. Chiu YC, Liao SF, Wu JF, Lin CY, Lee WC, Chen HL, et al. Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up. J Pediatr. 2014;165(4):767–72. e1.

    Article  CAS  PubMed  Google Scholar 

  39. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118(3):191–4.

    Article  PubMed  Google Scholar 

  40. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–54.

    Article  PubMed  Google Scholar 

  41. Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001–2010. J Clin Virol. 2013;58(2):396–400.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133(5):1458–65.

    Article  CAS  PubMed  Google Scholar 

  43. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139(2):483–90.

    Article  CAS  PubMed  Google Scholar 

  44. Martinot-Peignoux M, Lapalus M, Laouenan C, Lada O, Netto-Cardoso AC, Boyer N, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol. 2013;58(2):401–7.

    Article  CAS  PubMed  Google Scholar 

  45. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.

    Article  PubMed  Google Scholar 

  46. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145(11):1039–47.

    Article  CAS  PubMed  Google Scholar 

  47. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150(5):1051–4.

    Article  CAS  PubMed  Google Scholar 

  48. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58(2):546–54.

    Article  CAS  PubMed  Google Scholar 

  49. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921–31.

    Article  PubMed  Google Scholar 

  50. Chen G, Lin WY, Shen FM, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101(8):1797–803.

    Article  PubMed  Google Scholar 

  51. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12(9-10):S294–308.

    Article  CAS  PubMed  Google Scholar 

  52. Chen CJ, Yu MW, Wang CJ, Huang HY, Lin WC. Multiple risk factors of hepatocellular carcinoma: a cohort study of 13 737 male adults in Taiwan. J Gastroenterol Hepatol. 1993;8(S1):83–7.

    Article  Google Scholar 

  53. Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol. 2013;177(4):333–42.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(12):1636–45 e1–3.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(16):1134–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92(14):1159–64.

    Article  CAS  PubMed  Google Scholar 

  57. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26(34):5576–82.

    Article  PubMed  Google Scholar 

  58. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111–21.

    Article  CAS  PubMed  Google Scholar 

  59. Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis. 2011;32(6):876–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, et al. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in Taiwan. Cancer Epidem Biomar. 2014;23(8):1659–71.

    Article  CAS  Google Scholar 

  61. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011;29(27):3643–50.

    Article  PubMed  Google Scholar 

  62. Tang BQ, Kruger WD, Chen G, Shen FM, Lin WY, Mboup S, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol. 2004;72(1):35–40.

    Article  CAS  PubMed  Google Scholar 

  63. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240–8, 8 e1-2.

    Article  CAS  PubMed  Google Scholar 

  64. Sunbul M. Hepatitis B, virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–34.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5–11.

    Article  CAS  PubMed  Google Scholar 

  66. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265–72.

    Article  CAS  PubMed  Google Scholar 

  67. Yang HI, Lee MH, Liu J, Chen CJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol. 2014;20(20):6244–51.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437–44.

    Article  PubMed  Google Scholar 

  69. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–74.

    Article  PubMed  Google Scholar 

  70. Chen G, Lin WY, Shen FM, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005;34(1):132–7.

    Article  PubMed  Google Scholar 

  71. Montuclard C, Hamza S, Rollot F, Evrard P, Faivre J, Hillon P, et al. Causes of death in people with chronic HBV infection: a population-based cohort study. J Hepatol. 2015;62(6):1265–71.

    Article  PubMed  Google Scholar 

  72. Fwu CW, Chien YC, Nelson KE, Kirk GD, You SL, Kuo HS, et al. Mortality after chronic hepatitis B virus infection: a linkage study involving 2 million Parous women from Taiwan. J Infect Dis. 2010;201(7):1016–23.

    Article  PubMed  Google Scholar 

  73. Fwu CW, Chien YC, You SL, Nelson KE, Kirk GD, Kuo HS, et al. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of Parous women in Taiwan. Hepatology. 2011;53(4):1217–25.

    Article  PubMed  Google Scholar 

  74. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int. 2010;30(3):423–9.

    Article  PubMed  Google Scholar 

  75. Lao TT, Tse KY, Chan LY, Tam KF, Ho LF. HBsAg carrier status and the association between gestational diabetes with increased serum ferritin concentration in Chinese women. Diabetes Care. 2003;26(11):3011–6.

    Article  PubMed  Google Scholar 

  76. Spradling PR, Simons B, Narayanan M, Xing J, Homan C, Bulkow L, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection. J Viral Hepat. 2013;20(7):510–3.

    Article  CAS  PubMed  Google Scholar 

  77. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2(10):1104–8.

    Article  CAS  PubMed  Google Scholar 

  78. Michalak TI, Pardoe IU, Coffin CS, Churchill ND, Freake DS, Smith P, et al. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology. 1999;29(3):928–38.

    Article  CAS  PubMed  Google Scholar 

  79. Loriot MA, Marcellin P, Walker F, Boyer N, Degott C, Randrianatoavina I, et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol. 1997;27(2):251–8.

    Article  CAS  PubMed  Google Scholar 

  80. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management. Rev Med Virol. 2001;11(5):287–99.

    Article  CAS  PubMed  Google Scholar 

  81. Ishiga K, Kawatani T, Suou T, Tajima F, Omura H, Idobe Y, et al. Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol. 2001;73(1):115–8.

    Article  CAS  PubMed  Google Scholar 

  82. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–11.

    Article  CAS  PubMed  Google Scholar 

  83. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59(6):2092–100.

    Article  CAS  PubMed  Google Scholar 

  84. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86.

    Article  PubMed  Google Scholar 

  85. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123(4):1084–9.

    Article  PubMed  Google Scholar 

  86. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genomics Research Center, Academia Sinica, 128 Academia Road Section 2, Nankang, Taipei, 11529, Taiwan

    Chien-Jen Chen, Hwai-I Yang, Jessica Liu & Hui-Han Hu

  2. Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan

    Chien-Jen Chen

  3. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

    Mei-Hsuan Lee

Authors
  1. Chien-Jen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hwai-I Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei-Hsuan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jessica Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui-Han Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chien-Jen Chen .

Editor information

Editors and Affiliations

  1. Chang Gung University, Chang Gung Memorial Hospital, Taipei, Taiwan

    Yun-Fan Liaw

  2. INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France

    Fabien Zoulim

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chen, CJ., Yang, HI., Lee, MH., Liu, J., Hu, HH. (2016). Natural History of HBV Infection in the Community. In: Liaw, YF., Zoulim, F. (eds) Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-22330-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22330-8_12

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-22329-2

  • Online ISBN: 978-3-319-22330-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation